// App-Quantinova.ai

437 : Derazantinib (DZB) in combination with atezolizumab (AZB) in patients with solid tumors: Results from the dose-finding phase Ib substudy of FIDES-02.

Researchers

Presenter

  • Raghad Muhsin Abdul-Karim

Principal Investigators

  • Arvind Chaudhry

  • Anna Patrikidou

  • Alejandro Falcon Gonzalez

  • Fabricio Racca

  • Yohann Loriot

  • Damien Pouessel

  • Jean-Laurent Deville

  • Hyo Jin Lee

  • Frederique Cantero

  • Michalina Marszewska

  • Mikael Saulay

  • Stephan Braun

  • Rodryg Ramlau

Medical Centers

  • Texas Oncology, San Antonio, TX

  • Med Onc Assoc P S, Spokane, WA

  • Sarah Cannon Research Institute, London, United Kingdom

  • Medical Oncology Department. Hospital Universitario Virgen del Rocio, Seville, Spain

  • Intitute of Oncology of Barcelona, Barcelona, Spain

  • Department of Cancer Medicine, Institut Gustave Roussy, Paris-Sud University, Villejuif, France

  • Institut Claudius Regaud, IUCT-Oncopole, CRCT, Inserm, Toulouse, France

  • Hospital de la Timone, Marseille, France

  • Basilea Pharmaceutica International Ltd, Basel, Switzerland

  • Basilea Pharmaceutica, Basel, Switzerland

  • Basilea Pharmaceutica International Ltd, Basel, Switzerland

  • Poznan University of Medical Sciences, Poznan, Poland

Locations

  • United States

  • United Kingdom

  • Spain

  • France

  • Republic of South Korea

  • Switzerland

  • Poland

Companies

  • Basilea Pharmaceutic

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Fibroblast growth factor receptor

Drug/Treatment

  • Atezolizumab

Outcome

  • N/A

Study Design

  • Open Label

  • Cohort

Phase

  • I

Study Id's

  • NCT04045613

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved